Timothy J Hobday

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Treatment of neuroendocrine tumor liver metastases
    Mark A Lewis
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Hepatol 2012:973946. 2012
  2. ncbi request reprint Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma
    Timothy J Hobday
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:4574-80. 2002
  3. ncbi request reprint Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer
    Timothy J Hobday
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 2:161-9. 2002
  4. ncbi request reprint An overview of approaches to adjuvant therapy for colorectal cancer in the United States
    Timothy J Hobday
    Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 5:S11-8. 2005
  5. pmc North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane
    Kostandinos Sideras
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Clin Breast Cancer 12:387-91. 2012
  6. ncbi request reprint Medical management of pancreatic neuroendocrine tumors
    Thierry Delaunoit
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Gastroenterol 103:475-83; quiz 484. 2008
  7. ncbi request reprint Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors
    He Yu Zhang
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocrine 30:299-306. 2006
  8. ncbi request reprint Adjuvant therapy of colon cancer: a review
    Timothy J Hobday
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Clin Colorectal Cancer 1:230-6. 2002
  9. ncbi request reprint Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas
    Bettina Papouchado
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mod Pathol 18:1329-35. 2005
  10. ncbi request reprint Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival
    Frederike G I van Vilsteren
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Transpl 12:448-56. 2006

Collaborators

Detail Information

Publications16

  1. pmc Treatment of neuroendocrine tumor liver metastases
    Mark A Lewis
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Hepatol 2012:973946. 2012
    ..Finally, the experience with orthotopic liver transplant for neuroendocrine tumors is described...
  2. ncbi request reprint Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma
    Timothy J Hobday
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:4574-80. 2002
    ..To evaluate quality of life (QOL) and tumor response after administration of an oral chemotherapy regimen in patients with previously untreated metastatic colorectal cancer...
  3. ncbi request reprint Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer
    Timothy J Hobday
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 2:161-9. 2002
    ..Herein, we review recent developments in combination and sequential chemotherapy for metastatic colorectal cancer and the implications for the optimal treatment in these patients...
  4. ncbi request reprint An overview of approaches to adjuvant therapy for colorectal cancer in the United States
    Timothy J Hobday
    Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 5:S11-8. 2005
    ..For rectal cancer, optimal outcomes are dependent not only on the systemic therapy, but also on the expertise of the surgeon and the timing of RT, with improved local control and toxicity seen with preoperative therapy...
  5. pmc North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane
    Kostandinos Sideras
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Clin Breast Cancer 12:387-91. 2012
    ..Angiogenesis is an established target for the treatment of MBC. Aflibercept (VEGF-Trap) is a humanized fusion protein, which binds VEGF-A, VEGF-B, and PIGF-1 and -2...
  6. ncbi request reprint Medical management of pancreatic neuroendocrine tumors
    Thierry Delaunoit
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Gastroenterol 103:475-83; quiz 484. 2008
    ..However, we point out that much of the literature published to date includes noncomparative studies (mainly phase II studies), leading to thorny interpretation of the results...
  7. ncbi request reprint Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors
    He Yu Zhang
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocrine 30:299-306. 2006
    ..The other six genes did not show significant differences. These results suggest that increased methylation of RASSF1A and CTNNB1 may play important roles in progression and metastasis of small bowel carcinoid tumors...
  8. ncbi request reprint Adjuvant therapy of colon cancer: a review
    Timothy J Hobday
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Clin Colorectal Cancer 1:230-6. 2002
    ....
  9. ncbi request reprint Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas
    Bettina Papouchado
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mod Pathol 18:1329-35. 2005
    ....
  10. ncbi request reprint Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival
    Frederike G I van Vilsteren
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Transpl 12:448-56. 2006
    ..In conclusion, liver transplantation for patients with hepatic metastases from GEP is a viable therapeutic option in highly selected patients...
  11. doi request reprint Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437
    Monica M Reinholz
    Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55906, USA
    Clin Cancer Res 17:7183-93. 2011
    ....
  12. ncbi request reprint A single-center experience with inflammatory breast cancer, 1985-2003
    Rory L Smoot
    Department of Surgery, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Arch Surg 141:567-72; discussion 572-3. 2006
    ..quot;Up-front" surgery improves survival in inflammatory breast cancer (IBC)...
  13. ncbi request reprint Molecularly targeted therapies for breast cancer
    Timothy J Hobday
    Department of Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Cancer Control 12:73-81. 2005
    ....
  14. pmc Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score
    Arif H Kamal
    Division of Medical Oncology, Duke Comprehensive Cancer Center, Durham, North Carolina, USA
    Oncologist 16:1359-66. 2011
    ..Redwood City, CA) recurrence score (RS) is prognostic for recurrence and predictive of chemotherapy benefit. We explored the ability of oncologists to predict the RS using standard prognostic criteria...
  15. ncbi request reprint Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors
    Thierry Delaunoit
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:502-6. 2005
    ..This article reviews the evidence for the use of somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors based on a MEDLINE search of literature published from January 1970 to July 2003...
  16. ncbi request reprint Imatinib mesylate-induced interstitial pneumonitis
    Cynthia X Ma
    Mayo Clin Proc 78:1578-9. 2003